Valuation: RVL Pharmaceuticals plc

Market Cap 3L 3L 3L 2L 5L 3.19Cr 5L 31.65L 12.32L 1.61Cr 12.55L 12.28L 5.32Cr P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 1.33Cr 1.14Cr 1.07Cr 97.4L 1.84Cr 126.61Cr 1.86Cr 13Cr 4.9Cr 64Cr 4.99Cr 4.88Cr 211.54Cr EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.19
5 years 0
Extreme 1.0E-6
3.71
10 years 0
Extreme 1.0E-6
9.9
Manager TitleAgeSince
Chief Operating Officer 44 01/01/2016
Human Resources Officer - 01/01/2016
Date Insider Type Main position Quantity % Market Cap.
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
18/10/23
Altchem Ltd.
SellCompany 34,21,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 111
-0.62%+2.04%+2.21%+24.29% 5.17TCr
-0.09%-2.14%+492.60%+537.84% 4.53TCr
-0.32%+8.08%+37.97%+18.45% 4.27TCr
+1.18%+1.96%+21.95%+89.69% 4.28TCr
-2.27%-3.02%+14.22%+51.50% 3.29TCr
-0.96%+4.03%+31.55%+136.34% 1.71TCr
+0.41%+1.66% - - 1.66TCr
-0.32%+4.50%+12.66%+30.37% 1.5TCr
-0.31%+6.61%+81.37%+48.53% 1.42TCr
Average -0.35%+2.67%+86.82%+117.13% 2.78TCr
Weighted average by Cap. -0.37%+2.74%+104.51%+135.37%

Financials

2021 2022
Net sales 1.75Cr 1.5Cr 1.41Cr 1.28Cr 2.42Cr 166.85Cr 2.45Cr 17Cr 6.45Cr 84Cr 6.57Cr 6.43Cr 278.77Cr 4.97Cr 4.26Cr 3.99Cr 3.65Cr 6.88Cr 474.01Cr 6.95Cr 47Cr 18Cr 239.15Cr 19Cr 18Cr 791.99Cr
Net income -6.49Cr -5.56Cr -5.21Cr -4.76Cr -8.99Cr -618.91Cr -9.07Cr -61Cr -24Cr -312.26Cr -24Cr -24Cr -1.03TCr -5.17Cr -4.43Cr -4.15Cr -3.79Cr -7.15Cr -492.8Cr -7.23Cr -49Cr -19Cr -248.63Cr -19Cr -19Cr -823.38Cr
Net Debt 72.01L 61.71L 57.82L 52.81L 99.67L 69Cr 1.01Cr 6.82Cr 2.66Cr 35Cr 2.7Cr 2.64Cr 114.7Cr 1.29Cr 1.11Cr 1.04Cr 94.95L 1.79Cr 123.42Cr 1.81Cr 12Cr 4.77Cr 62Cr 4.86Cr 4.76Cr 206.21Cr
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
20/26/20 $0.000001 0.00% 83,004
19/26/19 $0.000001 0.00% 100
  1. Stock Market
  2. Stocks
  3. RVLPQ Stock